Da: GreatBookPrices, Columbia, MD, U.S.A.
EUR 147,08
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 145,61
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
Da: Ria Christie Collections, Uxbridge, Regno Unito
EUR 152,36
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. In.
Da: Ria Christie Collections, Uxbridge, Regno Unito
EUR 152,36
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. In.
Da: GreatBookPrices, Columbia, MD, U.S.A.
EUR 167,82
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 168,63
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
Da: preigu, Osnabrück, Germania
EUR 149,00
Quantità: 5 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Regulation of Genome Editing in Human iPS Cells | A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies | Hans-Georg Dederer (u. a.) | Taschenbuch | x | Englisch | 2023 | Springer | EAN 9783030930257 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Condizione: New.
Condizione: New. 1st ed. 2022 edition NO-PA16APR2015-KAP.
Lingua: Inglese
Editore: Springer International Publishing, Springer Nature Switzerland, 2023
ISBN 10: 3030930254 ISBN 13: 9783030930257
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 171,19
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells). Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies. This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers.
Lingua: Inglese
Editore: Springer International Publishing, Springer Nature Switzerland, 2022
ISBN 10: 303093022X ISBN 13: 9783030930226
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 171,19
Quantità: 1 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells). Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies. This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers.
Da: Revaluation Books, Exeter, Regno Unito
EUR 248,26
Quantità: 2 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. 344 pages. 9.25x6.10x0.72 inches. In Stock.
Da: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 134,27
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: new. Questo è un articolo print on demand.
Da: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 134,27
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: new. Questo è un articolo print on demand.
Lingua: Inglese
Editore: Springer, Berlin|Springer International Publishing|Springer, 2023
ISBN 10: 3030930254 ISBN 13: 9783030930257
Da: moluna, Greven, Germania
EUR 144,94
Quantità: Più di 20 disponibili
Aggiungi al carrelloKartoniert / Broschiert. Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibili.
Lingua: Inglese
Editore: Springer, Berlin|Springer International Publishing|Springer, 2022
ISBN 10: 303093022X ISBN 13: 9783030930226
Da: moluna, Greven, Germania
EUR 144,94
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibili.
Lingua: Inglese
Editore: Springer International Publishing, Springer Nature Switzerland Mai 2022, 2022
ISBN 10: 303093022X ISBN 13: 9783030930226
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
EUR 171,19
Quantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells). Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies. This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers. 344 pp. Englisch.
Lingua: Inglese
Editore: Springer International Publishing, Springer Nature Switzerland Mai 2023, 2023
ISBN 10: 3030930254 ISBN 13: 9783030930257
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
EUR 171,19
Quantità: 2 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells). Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies. This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers. 344 pp. Englisch.
Lingua: Inglese
Editore: Springer, Springer Mai 2023, 2023
ISBN 10: 3030930254 ISBN 13: 9783030930257
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 171,19
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Introduction.- Biological Aspects of Genome Editing in iPS Cells.- Ethical Aspects in the Context of Genome Editing.- Regulation of Genome Editing in iPS Cells: Germany.- Regulation of Genome Editing in iPS Cells: France.- Regulation of Genome Editing in iPS Cells: Switzerland.- Regulation of Genome Editing in iPS Cells: United States.- Regulation of Genome Editing in iPS Cells: Japan.- Regulation of Genome Editing in iPS Cells: Republic of Korea.- Comparative Analysis.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 344 pp. Englisch.
Lingua: Inglese
Editore: Springer, Springer Mai 2022, 2022
ISBN 10: 303093022X ISBN 13: 9783030930226
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 171,19
Quantità: 1 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Introduction.- Biological Aspects of Genome Editing in iPS Cells.- Ethical Aspects in the Context of Genome Editing.- Regulation of Genome Editing in iPS Cells: Germany.- Regulation of Genome Editing in iPS Cells: France.- Regulation of Genome Editing in iPS Cells: Switzerland.- Regulation of Genome Editing in iPS Cells: United States.- Regulation of Genome Editing in iPS Cells: Japan.- Regulation of Genome Editing in iPS Cells: Republic of Korea.- Comparative Analysis.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 344 pp. Englisch.
Da: Majestic Books, Hounslow, Regno Unito
EUR 234,85
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. Print on Demand.
Da: Majestic Books, Hounslow, Regno Unito
EUR 236,78
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. Print on Demand.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 235,93
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. PRINT ON DEMAND.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 235,24
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. PRINT ON DEMAND.